HER 2 LOW-EXPRESSING BREAST CANCER
Clinical trials for HER 2 LOW-EXPRESSING BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER 2 LOW-EXPRESSING BREAST CANCER trials appear
Sign up with your email to follow new studies for HER 2 LOW-EXPRESSING BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can switching between two powerful drugs beat advanced breast cancer?
Disease control Not yet recruitingThis study tests whether alternating two different targeted drugs (sacituzumab govitecan and trastuzumab deruxtecan) helps people with advanced HER2-low triple-negative breast cancer live longer compared to using just one drug alone. About 260 adults with metastatic or locally ad…
Matched conditions: HER 2 LOW-EXPRESSING BREAST CANCER
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated May 26, 2026 10:41 UTC
-
New study aims to improve treatment monitoring for HER2 low breast cancer
Knowledge-focused Not yet recruitingThis study looks at whether a type of PET-CT scan can better detect if the drug trastuzumab deruxtecan (T-DXd) is working in people with HER2 low metastatic breast cancer. The goal is to see if this scan can identify non-responders earlier than standard CT scans, potentially avoi…
Matched conditions: HER 2 LOW-EXPRESSING BREAST CANCER
Phase: NA • Sponsor: Centre Paul Strauss • Aim: Knowledge-focused
Last updated May 26, 2026 08:20 UTC